^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-08046052

    i
    Other names: PF-08046052, SGN-EGFRd2, LAVA-1223, LAVA-224×223, LAVA1223, LAVA224×223, PF08046052, LAVA 1223, LAVA 224×223, PF 08046052
    Associations

    News

    Trials
    Company:
    LAVA Therap, Pfizer
    Drug class:
    EGFR inhibitor, γδ TCR modulator
    Related drugs:
    Associations

    News

    Trials
    6ms
    SGNEGFRd2-001: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=290, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Jul 2029 --> Jan 2030 | Trial primary completion date: Jul 2028 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    PF-08046052
    9ms
    SGNEGFRd2-001: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=275, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Sep 2028 --> Jul 2029 | Trial primary completion date: Jul 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    PF-08046052
    2years
    A Study of SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=275, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement • EGFR rearrangement
    |
    PF-08046052
    over2years
    A Study of SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=275, Not yet recruiting, Seagen Inc.
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement • EGFR rearrangement
    |
    PF-08046052